[{"id":"5cfcbe7d-4d03-4117-95be-9b8d7199f4ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04146298","created_at":"2021-01-18T20:14:11.889Z","updated_at":"2024-07-02T16:35:38.229Z","phase":"Phase 1/2","brief_title":"Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer","source_id_and_acronym":"NCT04146298","lead_sponsor":"Changhai Hospital","biomarkers":" KRAS • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V • KRAS expression","tags":["KRAS • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V • KRAS expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/21/2021","start_date":" 10/21/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-09-01"},{"id":"ca26ef38-fd0d-4a77-8bfb-ec7325914e7f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01442649","created_at":"2021-01-18T05:58:51.140Z","updated_at":"2024-07-02T16:36:18.642Z","phase":"Phase 2","brief_title":"Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab","source_id_and_acronym":"NCT01442649","lead_sponsor":"UNICANCER","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • KRAS expression","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • KRAS expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 133","initiation":"Initiation: 12/01/2010","start_date":" 12/01/2010","primary_txt":" Primary completion: 10/01/2015","primary_completion_date":" 10/01/2015","study_txt":" Completion: 12/31/2017","study_completion_date":" 12/31/2017","last_update_posted":"2022-01-11"},{"id":"c9c5cc45-748a-4a71-a608-05bebad3c182","acronym":"","url":"https://clinicaltrials.gov/study/NCT05068206","created_at":"2021-10-05T20:00:18.001Z","updated_at":"2024-07-02T16:36:22.729Z","phase":"Phase 2","brief_title":"A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx","source_id_and_acronym":"NCT05068206","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS expression","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Focus V (anlotinib) • capecitabine • oxaliplatin • Anniko (penpulimab-kcqx)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 10/08/2021","start_date":" 10/08/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2021-10-20"},{"id":"b0fef793-7b81-42b4-ba49-db123c09fe43","acronym":"","url":"https://clinicaltrials.gov/study/NCT00614393","created_at":"2021-01-18T02:16:58.601Z","updated_at":"2024-07-02T16:37:08.137Z","phase":"Phase 2","brief_title":"Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)","source_id_and_acronym":"NCT00614393","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS wild-type • RAS wild-type • KRAS expression","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS wild-type • RAS wild-type • KRAS expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • irinotecan • dalotuzumab (MK 0646)"],"overall_status":"Completed","enrollment":" Enrollment 558","initiation":"Initiation: 12/24/2007","start_date":" 12/24/2007","primary_txt":" Primary completion: 06/01/2010","primary_completion_date":" 06/01/2010","study_txt":" Completion: 03/07/2012","study_completion_date":" 03/07/2012","last_update_posted":"2018-08-08"},{"id":"f0387d12-fa4e-40e1-addf-226e0d4ad5ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT00900328","created_at":"2021-01-18T03:28:03.237Z","updated_at":"2024-07-02T16:37:19.075Z","phase":"","brief_title":"Study of Tumor Samples From Patients With Lung Cancer","source_id_and_acronym":"NCT00900328","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" EGFR • KRAS • ALK • TP53 • MET • CBL","pipe":" | ","alterations":" TP53 mutation • KRAS mutation • EGFR mutation • EGFR expression • MET overexpression • MET expression • CBL mutation • ALK translocation • TP53 expression • KRAS expression","tags":["EGFR • KRAS • ALK • TP53 • MET • CBL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation • EGFR mutation • EGFR expression • MET overexpression • MET expression • CBL mutation • ALK translocation • TP53 expression • KRAS expression"],"overall_status":"Completed","enrollment":" Enrollment 280","initiation":"Initiation: 09/01/2008","start_date":" 09/01/2008","primary_txt":" Primary completion: 02/01/2012","primary_completion_date":" 02/01/2012","study_txt":" Completion: 09/01/2012","study_completion_date":" 09/01/2012","last_update_posted":"2017-08-08"},{"id":"8eff224f-dd6c-4358-93e8-9182bfd305b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT00837135","created_at":"2021-01-18T03:11:13.477Z","updated_at":"2024-07-02T16:37:29.739Z","phase":"Phase 1","brief_title":"GI-4000 With Adoptive Transfer in Pancreatic Cancer","source_id_and_acronym":"NCT00837135","lead_sponsor":"University of Pennsylvania","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12 • KRAS Q61L • KRAS expression","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12 • KRAS Q61L • KRAS expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GI-4000"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2008","start_date":" 01/01/2008","primary_txt":" Primary completion: 10/01/2009","primary_completion_date":" 10/01/2009","study_txt":" Completion: 10/01/2009","study_completion_date":" 10/01/2009","last_update_posted":"2016-08-17"}]